secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arbutus Biopharma Corp (ABUS)
CIK:        0001447028
Form:       8-K
Filed at:   2024-08-01T23:59:59+00:00
Accession:  0001171843-24-004324
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arbutus Q2 net loss $19.8M; cuts workforce 40%, extends cash runway to Q4 2026
------------------------------------------------------------------------------

- Net loss of $19.8M ($0.11 loss per share) vs $17.1M loss prior year; revenue $1.7M down from $4.7M.
- Workforce reduction of 40% (discontinuing HBV discovery); one-time restructuring charge $3-4M in Q3.
- Cash, cash equivalents & investments $148.5M; cash runway extended into Q4 2026 (2024 cash burn guidance $63-67M).
- IM-PROVE I data: 33% of patients achieved undetectable HBsAg; 67% for those with baseline HBsAg <1000 IU/mL.
- LNP litigation vs Moderna trial set for April 21, 2025; Pfizer/BioNTech ongoing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1447028/000117184324004324/0001171843-24-004324-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1447028/000117184324004324/f8k_080124.htm
  HTML page:      https://secwatch.observer/filing/0001171843-24-004324

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer